RT 102
Alternative Names: Parathyroid Hormone - Rani Therapeutics; RT-102Latest Information Update: 28 Mar 2025
At a glance
- Originator Rani Therapeutics
- Class Calcium regulators; Osteoporosis therapies; Peptide hormones; Recombinant proteins
- Mechanism of Action Calcium-sensing receptor agonists; Osteogenesis stimulants; Parathyroid hormone receptor agonists; Parathyroid hormone replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Osteoporosis
Most Recent Events
- 28 Mar 2025 No recent reports of development identified for phase-I development in Osteoporosis(In volunteers) in Australia (PO, Capsule)
- 21 Jun 2023 Efficacy and pharmacokinetics data from phase I in Osteoporosis released by Rani Therapeutics
- 15 Jun 2023 Pharmacokinetics data from a preclinical trial presented at the 105th Annual Meeting of the Endocrine Society (ENDO-2023)